The effect of cannabidiol in facilitating fear extinction and in attenuating fear retention and reinstatement in humans - The effect of cannabidiol (300 mg) on fear conditioning

niversiteit Utrecht0 个研究点目标入组 56 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•- Male or female volunteers between 18 and 30 years.
•- Judged to be in good physical and mental health on the basis of the medical history according to self-report.
•- Have a normal binocular acuity, corrected or uncorrected.
•- Female participants must declare they are on reliable birth control.

•- History of any disease, e.g. neurological disorders, psychiatric disorders, which in the opinion of the investigator may confound the results of the study.
•- Present any other conditions in that in the investigators*, the subjects* personal or the study physicians* opinion may confound the results of the study.
•- History of psychotic disorder/psychosis and/or having a first/second degree family member with (a history of) psychotic disorder/psychosis.
•- Current diagnosis of an Axis I or Axis II psychiatric disorder, or suffering from an Axis I or Axis II psychiatric disorder within 4 weeks prior to the study.
•- Current cardiac disease and/or history of cardiac disease.
•- Known hypersensitivity to CBD.
•- History of cannabinoids exopsure with adverse reactions.
•- History of severe allergy or general drug hypersensitivity.
•- History of abuse or current regular use of cannabis more than once a week.
•- Usage of psychoactive drugs in the four weeks prior to the study.
•- Current use of drugs of abuse or indications (urine screening)
•- History of epilepsy.
•- Pregnancy, i.e., a positive *-HCG urine test.
•- Lactating.
•- Reduced startle reactivity, defined as no discernable response in at least 3 out of the 12 startle stimuli presented at screening.

发起方